Enzalutamide Suppliers & Bulk Manufacturers
Available Forms: Tablet & Capsule
Available Strengths: Capsules- 40 mg, Tablet - 40 mg & 80 mg
Reference Brands: Xtandi® (EU & US)
Category: Oncology Cancer Care
Enzalutamide is available in Tablet & Capsule and strengths such as Capsules- 40 mg, Tablet - 40 mg & 80 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Enzalutamide is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Enzalutamide can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Enzalutamide is a next-generation androgen receptor inhibitor indicated for the treatment of prostate cancer, including metastatic castration-resistant and non-metastatic castration-resistant forms. Marketed as Xtandi®, it is available in 40 mg capsules and 40 mg/80 mg tablets in both the US and EU. It works by blocking androgen signaling pathways, helping slow disease progression. With proven clinical benefits and oral administration, Enzalutamide represents a high-value B2B oncology opportunity for pharmaceutical partners targeting the oncology segment in regulated markets such as the EU and United States.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
